Curcumin alters the pharmacokinetics of warfarin and clopidogrel in wistar rats but has no effect on anticoagulation or antiplatelet aggregation

Planta Medica

Volumn 79, Issue 11, 2013, Pages 971-977

  Liu, An Chang ^a   Zhao, Li Xia ^a   Lou, Hong Xiang ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

clopidogrel; curcumin; herb drug interaction; pharmacodynamics; pharmacokinetics; warfarin

Indexed keywords

CLOPIDOGREL; CURCUMIN; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PROTHROMBIN TIME; RAT; THROMBOCYTE AGGREGATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CHROMATOGRAPHY, LIQUID; CURCUMA; CURCUMIN; HERB-DRUG INTERACTIONS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RANDOM ALLOCATION; RATS; RATS, WISTAR; TANDEM MASS SPECTROMETRY; TICLOPIDINE; WARFARIN;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84881114627     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0032-1328652     Document Type: Article

References (33)

1. Eisenberg D. M., Davis R. B., Ettner S. L., Appel S., Wilkey S., Van Rompay M., Kessler R. C. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA: 1998; 280 1569 1575 (Pubitemid 28520643)
2. Richardson M. A., Sanders T., Palmer J. L., Greisinger A., Singletary S. E. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol: 2000; 18 2505 2514 (Pubitemid 30432515)
3. Ang-Lee M. K., Moss J., Yuan C. S. Herbal medicines and perioperative care. JAMA: 2001; 286 208 216 (Pubitemid 32640852)
4. Kaufman D. W., Kelly J. P., Rosenberg L., Anderson T. E., Mitchell A. A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA: 2002; 287 337 344 (Pubitemid 34251967)
5. Wold R. S., Lopez S. T., Yau C. L., Butler L. M., Pareo-Tubbeh S. L., Waters D. L., Garry P. J., Baumgartner R. N. Increasing trends in elderly persons use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. J Am Diet Assoc: 2005; 105 54 63 (Pubitemid 40075492)
6. Shahrokh L. E., Lukaszuk J. M., Prawitz A. D. Elderly herbal supplement users less satisfied with medical care than nonusers. J Am Diet Assoc: 2005; 105 1138 1140 (Pubitemid 40854206)
7. Kim D. C., Lee W., Bae J. S. Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro. Inflamm Res: 2011; 60 1161 1168
8. Karaman M., Firinci F., Cilaker S., Uysal P., Tugyan K., Yilmaz O., Uzuner N., Karaman O. Anti-inflammatory effects of curcumin in a murine model of chronic asthma. Allergol Immunopathol (Madr): 2012; 40 210 214
9. Li Y., Revalde J. L., Reid G., Paxton J. W. Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer Chemother Pharmacol: 2011; 68 603 610
10. Sharma R. A., Euden S. A., Platton S. L., Cooke D. N., Shafayat A., Hewitt H. R., Marczylo T. H., Morgan B., Hemingway D., Plummer S. M., Pirmohamed M., Gescher A. J., Steward W. P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res: 2004; 10 6847 6854 (Pubitemid 39383033)
11. Cheng A. L., Hsu C. H., Lin J. K., Hsu M. M., Ho Y. F., Shen T. S., Ko J. Y., Lin J. T., Lin B. R., Ming-Shiang W., Yu H. S., Jee S. H., Chen G. S., Chen T. M., Chen C. A., Lai M. K., Pu Y. S., Pan M. H., Wang Y. J., Tsai C. C., Hsieh C. Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res: 2001; 21 2895 2900
12. Dhillon N., Aggarwal B. B., Newman R. A., Wolff R. A., Kunnumakkara A. B., Abbruzzese J. L., Ng C. S., Badmaev V., Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res: 2008; 14 4491 4499
13. Li C., Kim D. K. Effects of curcumin on the pharmacokinetics of loratadine in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin. Biomol Ther: 2011; 19 364 370
14. Lee C. K., Ki S. H., Choi J. S. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin. Biopharm Drug Dispos: 2011; 32 245 251
15. Liu A. C., Zhao L. X., Xing J., Liu T., Du F. Y., Lou H. X. Pre-treatment with curcumin enhances plasma concentrations of losartan and its metabolite EXP3174 in rats. Biol Pharm Bull: 2012; 35 145 150
16. Gage B. F., Milligan P. E. Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements. Thromb Res: 2005; 117 55 59 discussion 65-67 (Pubitemid 41597030)
17. Yuan C. S., Wei G., Dey L., Karrison T., Nahlik L., Maleckar S., Kasza K., Ang-Lee M., Moss J. Brief communication: American ginseng reduces warfarins effect in healthy patients: a randomized, controlled trial. Ann Intern Med: 2004; 141 23 27
18. Engelsen J., Nielsen J. D., Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost: 2002; 87 1075 1076 (Pubitemid 34624893)
19. Tang M., Mukundan M., Yang J., Charpentier N., LeCluyse E. L., Black C., Yang D., Shi D., Yan B. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther: 2006; 319 1467 1476
20. Kazui M., Nishiya Y., Ishizuka T., Hagihara K., Farid N. A., Okazaki O., Ikeda T., Kurihara A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos: 2010; 38 92 99
21. Siller-Matula J. M., Lang I., Christ G., Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol: 2008; 52 1557 1563
22. Farid N. A., Payne C. D., Small D. S., Winters K. J., Ernest C. S. 2nd, Brandt J. T., Darstein C., Jakubowski J. A., Salazar D. E. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther: 2007; 81 735 741 (Pubitemid 46625113)
23. Jiang J., Wang W., Sun Y. J., Hu M., Li F., Zhu D. Y. Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage. Eur J Pharmacol: 2007; 561 54 62 (Pubitemid 46435844)
24. Yang C., Zhang X., Fan H., Liu Y. Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res: 2009; 1282 133 141
25. Mohanty I., Singh Arya D., Dinda A., Joshi S., Talwar K. K., Gupta S. K. Protective effects of Curcuma longa on ischemia-reperfusion induced myocardial injuries and their mechanisms. Life Sci: 2004; 75 1701 1711 (Pubitemid 38961794)
26. Volak L. P., Ghirmai S., Cashman J. R., Court M. H. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos: 2008; 36 1594 1605
27. Hou X. L., Takahashi K., Tanaka K., Tougou K., Qiu F., Komatsu K., Azuma J. Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways. Int J Pharm: 2008; 358 224 229
28. Zhang W., Tan T. M., Lim L. Y. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos: 2007; 35 110 115 (Pubitemid 46036483)
29. Wadelius M., Sorlin K., Wallerman O., Karlsson J., Yue Q. Y., Magnusson P. K., Wadelius C., Melhus H. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J: 2004; 4 40 48 (Pubitemid 38256604)
30. Taubert D., von Beckerath N., Grimberg G., Lazar A., Jung N., Goeser T., Kastrati A., Schomig A., Schomig E. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther: 2006; 80 486 501 (Pubitemid 44767878)
31. Williams J. A., Hyland R., Jones B. C., Smith D. A., Hurst S., Goosen T. C., Peterkin V., Koup J. R., Ball S. E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos: 2004; 32 1201 1208 (Pubitemid 39410902)
32. Mullangi R., Srinivas N. R. Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies. Biomed Chromatogr: 2009; 23 26 41
33. Nguyen T. A., Diodati J. G., Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol: 2005; 45 1157 1164 (Pubitemid 40523131)